


=> d ibib abs hitstr 1-2
 THE ESTIMATED COST FOR THIS REQUEST IS 11.28 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2008:1169030 CAPLUS
 DOCUMENT NUMBER: 149:493846
 TITLE: 5-N-Methylated Quindoline Derivatives as Telomeric G-Quadruplex Stabilizing Ligands: Effects of 5-N Positive Charge on Quadruplex Binding Affinity and Cell Proliferation
 AUTHOR(S): Lu, Yu-Jing; Ou, Tian-Miao; Tan, Jia-Heng; Hou, Jin-Qiang; Shao, Wei-Yan; Peng, Dan; Sun, Ning; Wang, Xiao-Dong; Wu, Wei-Bin; Bu, Xian-Zhang; Huang, Zhi-Shu; Ma, Dik-Lung; Wong, Kwok-Yin; Gu, Lian-Quan
 CORPORATE SOURCE: School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510080, Peop. Rep. China
 SOURCE: Journal of Medicinal Chemistry (2008), 51(20), 6381-6392
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 149:493846
 GI




AB A series of 5-N-Me quindoline (cryptolepine) derivs. as telomeric quadruplex ligands was synthesized and evaluated. The designed ligands possess a pos. charge at the 5-N position of the aromatic quindoline scaffold. The quadruplex binding of these compds. was evaluated by CD (CD) spectroscopy, fluorescence resonance energy transfer (FRET) melting assay, polymerase chain reaction (PCR) stop assay, NMR (NMR), and mol. modeling studies. Introduction of a pos. charge not only significantly improved the binding ability but also induced the selectivity toward antiparallel quadruplex, whereas the nonmethylated derivs. tended to stabilize hybrid-type quadruplexes. NMR and mol. modeling studies revealed that the ligands stacked on the external G-quartets and the pos. charged 5-N atom could contribute to the stabilizing ability. Long-term exposure of human cancer cells to I showed a remarkable cessation in population growth and cellular senescence phenotype and accompanied by a shortening of the telomere length.

IT 1072837-74-1P 1072837-78-5P 1072837-81-0P
 1072837-83-2P 1072837-99-0P 1072838-00-6P
 1072838-01-7P 1072838-02-8P 1072838-03-9P
 1072838-04-0P 1072838-05-1P 1072838-06-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and evaluation of cryptolepine derivs.)

RN 1072837-74-1 CAPLUS


CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-(5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072837-78-5 CAPLUS


CN 1,3-Propanediamine, N1,N1-dimethyl-N3-(5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072837-81-0 CAPLUS

CN 1,2-Ethanediamine, N1,N1-diethyl-N2-(5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)




● HI

10/580, 140

RN 1072837-83-2 CAPLUS


CN 1,3-Propanediamine, N1,N1-diethyl-N3-(5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072837-99-0 CAPLUS


CN 1,2-Ethanediamine, N2-(7-fluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-dimethyl-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072838-00-6 CAPLUS


CN 1,3-Propanediamine, N3-(7-fluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-dimethyl-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072838-01-7 CAPLUS


CN 1,2-Ethanediamine, N1,N1-diethyl-N2-(7-fluoro-5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072838-02-8 CAPLUS


CN 1,3-Propanediamine, N1,N1-diethyl-N3-(7-fluoro-5-methyl-5H-quindolin-11-yl)-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072838-03-9 CAPLUS


CN 1,2-Ethanediamine, N2-(7,9-difluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-dimethyl-, hydriodide (1:1) (CA INDEX NAME)



● HI


RN 1072838-04-0 CAPLUS

CN 1,3-Propanediamine, N3-(7,9-difluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-dimethyl-, hydriodide (1:1) (CA INDEX NAME)




● HI

RN 1072838-05-1 CAPLUS
 CN 1,2-Ethanediamine, N2-(7,9-difluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-diethyl-, hydriodide (1:1) (CA INDEX NAME)



● HI

RN 1072838-06-2 CAPLUS
 CN 1,3-Propanediamine, N3-(7,9-difluoro-5-methyl-5H-quindolin-11-yl)-N1,N1-diethyl-, hydriodide (1:1) (CA INDEX NAME)



● HI

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:523449 CAPLUS

DOCUMENT NUMBER: 143:59844

TITLE: A preparation of antitumor quinoline derivatives

INVENTOR(S): Aymami Bofarull, Juan; Coll Capella, Miquel; Llebaria Soldevila, Amadeo; Navarro Munoz, Isabel
 PATENT ASSIGNEE(S): Crystax Pharmaceuticals S.L., Spain; Consejo Superior de Investigaciones Cientificas; Universitat Politecnica de Catalunya
 SOURCE: PCT Int. Appl., 39 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005054236	A1	20050616	WO 2004-EP13106	20041118
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1687304	A1	20060809	EP 2004-797988	20041118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
JP 2007511573	T	20070510	JP 2006-540327	20041118
US 20070105784	A1	20070510	US 2006-580140	20060519
PRIORITY APPLN. INFO.:			ES 2003-2821	A 20031120
			WO 2004-EP13106	W 20041118

OTHER SOURCE(S): MARPAT 143:59844

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The invention relates to a preparation of antitumor quinoline derivs. of formula G1-L-G2 [wherein: G1 is quinoline derivative, L is a single bond or a linking radical; G2 is H, quinoline derivative, or C-9 radical of acridine, etc.]. The invention compds. are intercalators, compds. that bind between DNA base pairs. The in vitro cytotoxicity of the compds. was evaluated by colorimetric assays with tetrazole salts on Jurkat clone E6-1 and on GLC-4, human leukemia and carcinoma cell lines. For instance, indoloquinoline derivative I (Jurkat clone E6-1, IC50 = 1.42 μ M) was prepared via amidation of 10H-indolo[3,2-b]-1-carboxylic acid by carbamic acid derivative II, decarboxylation of the obtained amide, and subsequent amidation of 9-acridinecarboxylic acid by the obtained amine III (yields: 1st amidation - 70%, decarboxylation - 92%, 2nd amidation - 50%).

IT 854190-47-9P 854190-53-7P 854190-56-0P
 854190-70-8P 854190-76-4P 854190-81-1P
 854190-92-4P 854190-96-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of antitumor quinoline derivs.)

10/580, 140


RN 854190-47-9 CAPLUS

CN 5H-Quindoline-11-carboxamide, N,N'-(methylimino)di-3,1-propanediyl]bis[5-methyl- (9CI) (CA INDEX NAME)




RN 854190-53-7 CAPLUS

CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-(5-methyl-5H-quindolin-11-yl)- (CA INDEX NAME)



RN 854190-56-0 CAPLUS


CN 1,3-Propanediamine, N-methyl-N'-(5-methyl-5H-quindolin-11-yl)-N-[3-[(5-methyl-5H-quindolin-11-yl)amino]propyl]- (9CI) (CA INDEX NAME)



RN 854190-70-8 CAPLUS

CN 1,3-Propanediamine, N1,N1-dimethyl-N3-(5-methyl-5H-quindolin-11-yl)- (CA INDEX NAME)


10/580, 140




RN 854190-76-4 CAPLUS

CN 5H-Quindoline-11-carboxamide, N,N'-(1,3-propanediylbis[(methylimino)-2,1-ethanediyl])bis[5-methyl- (9CI) (CA INDEX NAME)]

PAGE 1-A




PAGE 1-B




RN 854190-81-1 CAPLUS

CN 5H-Quindoline-11-carboxamide, N,N'-(1,2-ethanediylbis[(methylimino)-2,1-ethanediyl])bis[5-methyl- (9CI) (CA INDEX NAME)]

PAGE 1-A




PAGE 1-B




RN 854190-92-4 CAPLUS

CN 1,3-Propanediamine, N,N'-dimethyl-N,N'-bis[2-[(5-methyl-5H-quindolin-11-yl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 854190-96-8 CAPLUS

CN 1,2-Ethanediamine, N,N'-dimethyl-N,N'-bis[2-[(5-methyl-5H-quindolin-11-


10/580, 140

yl)amino]ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 854190-49-1 854190-79-7 854190-83-3
854190-94-6 854190-98-0

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of antitumor quinoline derivs.)


RN 854190-49-1 CAPLUS

CN 5H-Quindoline-11-carboxamide, N-[3-(3-aminopropyl)methylamino]propyl-5-methyl- (CA INDEX NAME)




RN 854190-79-7 CAPLUS

CN 5H-Quindoline-11-carboxamide, N-[2-[3-[(2-aminoethyl)methylamino]propyl]methylamino]ethyl]-5-methyl- (CA INDEX NAME)




RN 854190-83-3 CAPLUS

CN 5H-Quindoline-11-carboxamide, N-[2-[2-[(2-aminoethyl)methylamino]ethyl]methylamino]ethyl]-5-methyl- (CA INDEX NAME)




RN 854190-94-6 CAPLUS


CN 1,3-Propanediamine, N1-(2-aminoethyl)-N1,N3-dimethyl-N3-[2-[(5-methyl-5H-quindolin-11-yl)amino]ethyl]- (CA INDEX NAME)




RN 854190-98-0 CAPLUS
 CN 1,2-Ethanediamine, N1-(2-aminoethyl)-N1,N2-dimethyl-N2-[2-[(5-methyl-5H-quindolin-11-yl)amino]ethyl]- (CA INDEX NAME)



IT 854190-58-2P 854190-60-6P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of antitumor quinoline derivs.)
 RN 854190-58-2 CAPLUS
 CN Carbamic acid, [3-[methyl[3-[(5-methyl-5H-quindolin-11-yl)amino]propyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 854190-60-6 CAPLUS
 CN 1,3-Propanediamine, N1-(3-aminopropyl)-N1-methyl-N3-(5-methyl-5H-quindolin-11-yl)- (CA INDEX NAME)



10/580,140

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 11:14:59 ON 26 JUN 2009)

FILE 'REGISTRY' ENTERED AT 11:15:33 ON 26 JUN 2009


L1 STRUCTURE UPLOADED
L2 1 S L1
L3 37 S L1 FULL

FILE 'CPLUS' ENTERED AT 11:16:11 ON 26 JUN 2009

L4 2 S L3

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 O,N

Structure attributes must be viewed using STN Express query preparation.

=>